KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Tax Provisions (2021 - 2025)

Rigel Pharmaceuticals (RIGL) has 3 years of Tax Provisions data on record, last reported at -$245.4 million in Q4 2025.

  • For Q4 2025, Tax Provisions fell 27949.15% year-over-year to -$245.4 million; the TTM value through Dec 2025 reached -$245.2 million, down 27931.67%, while the annual FY2025 figure was -$245.2 million, 27931.67% down from the prior year.
  • Tax Provisions reached -$245.4 million in Q4 2025 per RIGL's latest filing, down from -$280000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $1.8 million in Q1 2021 and bottomed at -$245.4 million in Q4 2025.
  • Average Tax Provisions over 3 years is -$27.1 million, with a median of -$100000.0 recorded in 2021.
  • The widest YoY moves for Tax Provisions: up 27949.15% in 2025, down 27949.15% in 2025.
  • A 3-year view of Tax Provisions shows it stood at -$100000.0 in 2021, then surged by 981.0% to $881000.0 in 2024, then tumbled by 27949.15% to -$245.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were -$245.4 million in Q4 2025, -$280000.0 in Q3 2025, and $369000.0 in Q2 2025.